Physician profile
Juliette H Williams
NPI 1306475553
$5,726.60
in general payments reported to CMS, 2019-2025
44 companies · $2,412 in 2025
The $2,412 reported for 2025 was more than what 98% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.38 · 2023: $1,131 · 2024: $2,169 · 2025: $2,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,608 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,608.18 |
| Education | $104.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $869.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $650.92 | 2023-2025 | Lynparza, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $561.54 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $315.69 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Regeneron Healthcare Solutions, INC. | $263.86 | 2023-2025 | Libtayo |
| Celgene Corporation | $212.86 | 2023-2024 | Pomalyst, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $177.35 | 2024-2025 | |
| Genzyme Corporation | $173.22 | 2023-2025 | |
| Lilly USA, LLC | $172.43 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $169.15 | 2023-2025 | Fotivda |
| Dendreon Pharmaceuticals LLC | $166.02 | 2023-2025 | Provenge |
| Beone Medicines USA, INC. | $146.33 | 2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $119.91 | 2024-2025 | Iclusig, Ninlaro |
| Astellas Pharma US INC | $118.26 | 2024-2025 | Vyloy, Padcev |
| Abbvie INC. | $115.15 | 2024-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $108.16 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Incyte Corporation | $108.14 | 2023-2025 | Jakafi, Monjuvi, Jakafi |
| Pharmacosmos Therapeutics INC. | $100.14 | 2023-2025 | Monoferric, Cosela |
| Amgen INC. | $89.62 | 2023 | Blincyto, Kyprolis, Evenity |
| Seagen INC. | $83.26 | 2023 | Adcetris, Tivdak, Padcev |
| Taiho Oncology, INC. | $80.38 | 2024-2025 | |
| Sobi, INC | $75.19 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $69.29 | 2023 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $68.04 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Eisai INC. | $64.26 | 2024-2025 | |
| Janssen Biotech, INC. | $63.12 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Mirati Therapeutics, INC. | $60.26 | 2024 | Krazati |
| Exelixis INC. | $60.12 | 2024 | Cabometyx |
| Geron Corporation | $55.91 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $52.79 | 2025 | |
| Beigene USA, INC. | $51.70 | 2024 | Brukinsa |
| Gilead Sciences, INC. | $42.74 | 2024-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $40.70 | 2025 | |
| Emd Serono, INC. | $32.42 | 2024 | |
| Caris Mpi, INC. | $23.96 | 2025 | Mi Cancer Seek |
| Grifols USA, LLC | $21.08 | 2023 | Gamunex-C |
| Coherus Oncology, INC. | $20.84 | 2025 | Loqtorzi |
| Tempus Ai, INC | $19.98 | 2024 | |
| Stemline Therapeutics INC. | $19.34 | 2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.42 | 2023 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $17.12 | 2024 | Ultomiris |
| Kite Pharma, INC. | $16.59 | 2025 | Yescarta |
| Myriad Genetic Laboratories, INC. | $15.96 | 2024 | Myrisk |
| Iovance Biotherapeutics, INC. | $14.43 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juliette Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.